L-type calcium channel antagonist isradipine age-dependently decreases plaque associated dystrophic neurites in 5XFAD mouse model

[1]  R. Nixon,et al.  Faulty autolysosome acidification in Alzheimer’s disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques , 2022, Nature Neuroscience.

[2]  R. Vassar,et al.  Oral nimodipine treatment has no effect on amyloid pathology or neuritic dystrophy in the 5XFAD mouse model of amyloidosis , 2022, PloS one.

[3]  Benjamin A. Logsdon,et al.  Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study , 2021, Frontiers in Aging Neuroscience.

[4]  A. Stroh,et al.  Acitretin reverses early functional network degradation in a mouse model of familial Alzheimer’s disease , 2021, Scientific Reports.

[5]  A. Mortazavi,et al.  Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer’s disease , 2021, bioRxiv.

[6]  O. Thibault,et al.  Electrophysiological and Imaging Calcium Biomarkers of Aging in Male and Female 5×FAD Mice , 2020, Journal of Alzheimer's disease : JAD.

[7]  Roger J. Thompson,et al.  Limiting RyR2 Open Time Prevents Alzheimer’s Disease-Related Neuronal Hyperactivity and Memory Loss but Not β-Amyloid Accumulation , 2020, Cell reports.

[8]  B. Ryffel,et al.  Hippocampal interleukin-33 mediates neuroinflammation-induced cognitive impairments , 2020, Journal of Neuroinflammation.

[9]  Jian Li,et al.  Verapamil extends lifespan in Caenorhabditis elegans by inhibiting calcineurin activity and promoting autophagy , 2020, Aging.

[10]  S. Hopp.  Targeting microglia L‐type voltage‐dependent calcium channels for the treatment of central nervous system disorders , 2020, Journal of neuroscience research.

[11]  M. Carrillo,et al.  Translational animal models for Alzheimer's disease: An Alzheimer's Association Business Consortium Think Tank , 2020, Alzheimer's & dementia.

[12]  A. Oblak,et al.  Improving preclinical to clinical translation in Alzheimer's disease research , 2020, Alzheimer's & dementia.

[13]  Makoto Ishii,et al.  Amyloid-Beta Modulates Low-Threshold Activated Voltage-Gated L-Type Calcium Channels of Arcuate Neuropeptide Y Neurons Leading to Calcium Dysregulation and Hypothalamic Dysfunction , 2019, The Journal of Neuroscience.

[14]  H. Saegusa,et al.  Blockade of microglial Cav1.2 Ca2+ channel exacerbates the symptoms in a Parkinson’s disease model , 2019, Scientific Reports.

[15]  Andrew R. Bassett,et al.  Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing , 2019, Nature Communications.

[16]  Xiongwei Zhu,et al.  Sequential formation of different layers of dystrophic neurites in Alzheimer’s brains , 2019, Molecular Psychiatry.

[17]  R. Segurado,et al.  Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial , 2018, PLoS medicine.

[18]  D. Surmeier,et al.  Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress , 2018, The Journal of clinical investigation.

[19]  J. Hanson,et al.  Microglia in Alzheimer’s disease , 2018, The Journal of cell biology.

[20]  Jing Zhang,et al.  Amyloid β Protein Aggravates Neuronal Senescence and Cognitive Deficits in 5XFAD Mouse Model of Alzheimer's Disease , 2016, Chinese medical journal.

[21]  M. Janahmadi,et al.  Calcium channel blockade attenuates abnormal synaptic transmission in the dentate gyrus elicited by entorhinal amyloidopathy , 2016, Synapse.

[22]  Shery Jacob,et al.  A simple practice guide for dose conversion between animals and human , 2016, Journal of basic and clinical pharmacy.

[23]  A. Ballabio,et al.  Neuronal-Targeted TFEB Accelerates Lysosomal Degradation of APP, Reducing Aβ Generation and Amyloid Plaque Pathogenesis , 2015, The Journal of Neuroscience.

[24]  P. De Camilli,et al.  Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer’s disease amyloid plaques , 2015, Proceedings of the National Academy of Sciences.

[25]  G. Wenk,et al.  Calcium dysregulation via L-type voltage-dependent calcium channels and ryanodine receptors underlies memory deficits and synaptic dysfunction during chronic neuroinflammation , 2015, Journal of Neuroinflammation.

[26]  X. Gasull,et al.  The L-type voltage-gated calcium channel modulates microglial pro-inflammatory activity , 2015, Molecular and Cellular Neuroscience.

[27]  J. Grutzendler,et al.  Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques , 2014, Nature Communications.

[28]  T. Maniatis,et al.  An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex , 2014, The Journal of Neuroscience.

[29]  Jung-jae Kim,et al.  Pharmacological correction of obesity-induced autophagy arrest using calcium channel blockers , 2014, Nature Communications.

[30]  A. Dhanushkodi,et al.  Abnormal vibrissa‐related behavior and loss of barrel field inhibitory neurons in 5xFAD transgenics , 2014, Genes, brain, and behavior.

[31]  Nina Daschil,et al.  Short- and Long-Term Treatment of Mouse Cortical Primary Astrocytes with β-Amyloid Differentially Regulates the mRNA Expression of L-Type Calcium Channels , 2014, Pharmacology.

[32]  O. Garaschuk,et al.  Impairment of in vivo calcium signaling in amyloid plaque-associated microglia , 2014, Acta Neuropathologica.

[33]  R. Nixon,et al.  Lysosome and calcium dysregulation in Alzheimer's disease: partners in crime. , 2013, Biochemical Society transactions.

[34]  O. Garaschuk,et al.  Microglial calcium signaling in the adult, aged and diseased brain. , 2013, Cell calcium.

[35]  F. Di Virgilio,et al.  Nimodipine inhibits IL‐1β release stimulated by amyloid β from microglia , 2012, British journal of pharmacology.

[36]  E. Holzbaur,et al.  Autophagosomes initiate distally and mature during transport toward the cell soma in primary neurons , 2012, The Journal of cell biology.

[37]  D. Surmeier,et al.  CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease , 2012, Nature Communications.

[38]  H. Rhim,et al.  Effects of amyloid-β peptides on voltage-gated L-type CaV1.2 and CaV1.3 Ca2+ channels , 2011, Molecules and cells.

[39]  J. Disterhoft,et al.  Mechanisms underlying basal and learning-related intrinsic excitability in a mouse model of Alzheimer's disease , 2011, Neurobiology of Aging.

[40]  William A Catterall,et al.  Voltage-Gated Calcium Channels , 2011 .

[41]  D. Paris,et al.  Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier. , 2011, European journal of pharmacology.

[42]  Sooyeon Lee,et al.  Lysosomal Proteolysis Inhibition Selectively Disrupts Axonal Transport of Degradative Organelles and Causes an Alzheimer's-Like Axonal Dystrophy , 2011, The Journal of Neuroscience.

[43]  J. Quinn,et al.  A translational continuum of model systems for evaluating treatment strategies in Alzheimer’s disease: isradipine as a candidate drug , 2011, Disease Models & Mechanisms.

[44]  C. Volmar,et al.  Selective Antihypertensive Dihydropyridines Lower Aβ Accumulation by Targeting both the Production and the Clearance of Aβ across the Blood-Brain Barrier , 2011, Molecular medicine.

[45]  J. Quinn,et al.  L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease , 2011, Neurobiology of Disease.

[46]  D. Wales,et al.  Transmembrane structures for Alzheimer's Aβ(1-42) oligomers. , 2010, Journal of the American Chemical Society.

[47]  M. Ares,et al.  Purification of RNA using TRIzol (TRI reagent). , 2010, Cold Spring Harbor protocols.

[48]  Michael J. Berridge,et al.  Calcium hypothesis of Alzheimer’s disease , 2010, Pflügers Archiv - European Journal of Physiology.

[49]  V. Haroutunian,et al.  Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons , 2009, Neurology.

[50]  Xiaoming Hu,et al.  Nimodipine protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation , 2009, Neuropharmacology.

[51]  Arthur Konnerth,et al.  Clusters of Hyperactive Neurons Near Amyloid Plaques in a Mouse Model of Alzheimer's Disease , 2008, Science.

[52]  Ilya Bezprozvanny,et al.  Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease , 2008, Trends in Neurosciences.

[53]  S. Hickman,et al.  Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice , 2008, The Journal of Neuroscience.

[54]  Brian J. Bacskai,et al.  Aβ Plaques Lead to Aberrant Regulation of Calcium Homeostasis In Vivo Resulting in Structural and Functional Disruption of Neuronal Networks , 2008, Neuron.

[55]  F. Haiss,et al.  Dynamics of the Microglial/Amyloid Interaction Indicate a Role in Plaque Maintenance , 2008, The Journal of Neuroscience.

[56]  F. LaFerla,et al.  Increased intraneuronal resting [Ca2+] in adult Alzheimer’s disease mice , 2008, Journal of neurochemistry.

[57]  D. Fowler,et al.  Partial Restoration of Mutant Enzyme Homeostasis in Three Distinct Lysosomal Storage Disease Cell Lines by Altering Calcium Homeostasis , 2008, PLoS biology.

[58]  Grace E. Stutzmann.  The Pathogenesis of Alzheimers Disease—Is It a Lifelong “Calciumopathy”? , 2007, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[59]  V. Bolivar,et al.  Habituation in rodents: A review of behavior, neurobiology, and genetics , 2006, Neuroscience & Biobehavioral Reviews.

[60]  J. Brion,et al.  Calcium-mediated Transient Phosphorylation of Tau and Amyloid Precursor Protein Followed by Intraneuronal Amyloid-β Accumulation* , 2006, Journal of Biological Chemistry.

[61]  M. Ohno,et al.  Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.

[62]  J. Shine,et al.  Acceleration of Amyloid β-Peptide Aggregation by Physiological Concentrations of Calcium* , 2006, Journal of Biological Chemistry.

[63]  J. Disterhoft,et al.  Pharmacological and molecular enhancement of learning in aging and Alzheimer’s disease , 2006, Journal of Physiology-Paris.

[64]  A. Burgo,et al.  Nimodipine selectively stimulates β-amyloid 1–42 secretion by a mechanism independent of calcium influx blockage , 2006, Neurobiology of Aging.

[65]  N. Heintz,et al.  Autophagy and Its Possible Roles in Nervous System Diseases, Damage and Repair , 2005, Autophagy.

[66]  R. Brookmeyer,et al.  Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging , 2005, Neurobiology of Aging.

[67]  Diane Lipscombe,et al.  L-type calcium channels: the low down. , 2004, Journal of neurophysiology.

[68]  W. Streit,et al.  Microglia and Alzheimer's disease pathogenesis , 2004, Journal of neuroscience research.

[69]  P. Dayer,et al.  Influence of input rates on (±)-isradipine haemodynamics and concentration-effect relationship in healthy volunteers , 2004, European Journal of Clinical Pharmacology.

[70]  F. Tse,et al.  Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man , 2004, European Journal of Clinical Pharmacology.

[71]  F. LaFerla.  Calcium dyshomeostasis and intracellular signalling in alzheimer's disease , 2002, Nature Reviews Neuroscience.

[72]  Jan A Staessen,et al.  The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002, Archives of internal medicine.

[73]  J. Birks,et al.  Nimodipine for primary degenerative, mixed and vascular dementia. , 2002, The Cochrane database of systematic reviews.

[74]  A. Koschak,et al.  α1D (Cav1.3) Subunits Can Form L-type Ca2+ Channels Activating at Negative Voltages* , 2001, The Journal of Biological Chemistry.

[75]  I Izquierdo,et al.  Role of hippocampal signaling pathways in long-term memory formation of a nonassociative learning task in the rat. , 2000, Learning & memory.

[76]  Shuxian Hu,et al.  β-Chemokines and human immunodeficiency virus type-1 proteins evoke intracellular calcium increases in human microglia , 2000, Neuroscience.

[77]  G. McCormack,et al.  Neurochemical Diversity of Dystrophic Neurites in the Early and Late Stages of Alzheimer's Disease , 1999, Experimental Neurology.

[78]  M. Salmona,et al.  Activation of microglial cells by PrP and β-amyloid fragments raises intracellular calcium through L-type voltage sensitive calcium channels , 1999, Brain Research.

[79]  S. Yamada,et al.  Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists. , 1997, Life sciences.

[80]  D. Selkoe,et al.  Caffeine Stimulates Amyloid β‐Peptide Release from β‐Amyloid Precursor Protein‐Transfected HEK293 Cells , 1997 .

[81]  R. Petersen,et al.  Nimodipine in the Treatment of Probable Alzheimer’s Disease , 1996 .

[82]  C. Colton,et al.  K+ modulation of microglial superoxide production: involvement of voltage-gated Ca2+ channels. , 1994, The American journal of physiology.

[83]  D. Selkoe,et al.  Calcium ionophore increases amyloid beta peptide production by cultured cells. , 1994, Biochemistry.

[84]  C. Cotman,et al.  Rapid Communication: Ca2+ Channel Blockers Attenuate β‐Amyloid Peptide Toxicity to Cortical Neurons in Culture , 1994 .

[85]  E. Rojas,et al.  Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[86]  G. Tollefson.  Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia , 1990, Biological Psychiatry.

[87]  F. Tse,et al.  Bioavailability of isradipine in young and old rats: Effect of mode of administration , 1989, The Journal of pharmacy and pharmacology.

[88]  Zaven S. Khachaturian,et al.  Hypothesis on the Regulation of Cytosol Calcium Concentration and the Aging Brain , 1987, Neurobiology of Aging.